UK markets open in 3 minutes
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    20,052.24
    +441.40 (+2.25%)
     
  • CRUDE OIL

    91.89
    -0.04 (-0.04%)
     
  • GOLD FUTURES

    1,800.40
    -13.30 (-0.73%)
     
  • DOW

    33,309.51
    +535.11 (+1.63%)
     
  • BTC-GBP

    20,106.36
    +1,245.69 (+6.60%)
     
  • CMC Crypto 200

    578.09
    +46.87 (+8.82%)
     
  • ^IXIC

    12,854.80
    +360.88 (+2.89%)
     
  • ^FTAS

    4,150.68
    +21.29 (+0.52%)
     

Could This Be Moderna's Ticket to Long-Term Success?

·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Moderna (NASDAQ: MRNA) waited a long time to reach this important moment: the authorization of its vaccine in infants and children. This month, the FDA authorized the vaccine for both teens and children ages six months and older, and vaccine rollout has begun for the youngest group. Could this new authorization be Moderna's ticket to long-term success?

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting